Shots:
Ian spoke about the study design of the clinical trials of its lead iNKT agonists
He also emphasized the advancement of novel immunotherapies through new collaborations
The interview provides a gist of Portage's development plan for its pipeline and various options to improve cancer treatment
Smriti: Explain the details (MOA, ROA, formulations, etc.) of PORT-2 & PORT-3?…
